1
Participants
Start Date
February 29, 2008
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
PEG-interferon alfa-2b
administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
Sorafenib
gene expression analysis
polymerase chain reaction
reverse transcriptase-polymerase chain reaction
flow cytometry
immunoenzyme technique
laboratory biomarker analysis
Ohio State University Comprehensive Cancer Center, Columbus
Collaborators (1)
Schering-Plough
INDUSTRY
Thomas Olencki
OTHER